6op5
From Proteopedia
(Difference between revisions)
| Line 3: | Line 3: | ||
<StructureSection load='6op5' size='340' side='right'caption='[[6op5]], [[Resolution|resolution]] 2.70Å' scene=''> | <StructureSection load='6op5' size='340' side='right'caption='[[6op5]], [[Resolution|resolution]] 2.70Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
| - | <table><tr><td colspan='2'>[[6op5]] is a 6 chain structure. This structure supersedes the now removed PDB entry [http://oca.weizmann.ac.il/oca-bin/send-pdb?obs=1&id=6co0 6co0]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6OP5 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6OP5 FirstGlance]. <br> | + | <table><tr><td colspan='2'>[[6op5]] is a 6 chain structure with sequence from [http://en.wikipedia.org/wiki/Piper_methysticum Piper methysticum]. This structure supersedes the now removed PDB entry [http://oca.weizmann.ac.il/oca-bin/send-pdb?obs=1&id=6co0 6co0]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6OP5 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6OP5 FirstGlance]. <br> |
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=WCA:P-COUMAROYL-COA'>WCA</scene></td></tr> | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=WCA:P-COUMAROYL-COA'>WCA</scene></td></tr> | ||
<tr id='NonStdRes'><td class="sblockLbl"><b>[[Non-Standard_Residue|NonStd Res:]]</b></td><td class="sblockDat"><scene name='pdbligand=60F:(2~{R})-2-AZANYL-3-[(~{E})-3-(4-HYDROXYPHENYL)PROP-2-ENOYL]SULFANYL-PROPANOIC+ACID'>60F</scene></td></tr> | <tr id='NonStdRes'><td class="sblockLbl"><b>[[Non-Standard_Residue|NonStd Res:]]</b></td><td class="sblockDat"><scene name='pdbligand=60F:(2~{R})-2-AZANYL-3-[(~{E})-3-(4-HYDROXYPHENYL)PROP-2-ENOYL]SULFANYL-PROPANOIC+ACID'>60F</scene></td></tr> | ||
| Line 9: | Line 9: | ||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6op5 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6op5 OCA], [http://pdbe.org/6op5 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6op5 RCSB], [http://www.ebi.ac.uk/pdbsum/6op5 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6op5 ProSAT]</span></td></tr> | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6op5 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6op5 OCA], [http://pdbe.org/6op5 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6op5 RCSB], [http://www.ebi.ac.uk/pdbsum/6op5 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6op5 ProSAT]</span></td></tr> | ||
</table> | </table> | ||
| + | <div style="background-color:#fffaf0;"> | ||
| + | == Publication Abstract from PubMed == | ||
| + | Kava (Piper methysticum) is an ethnomedicinal shrub native to the Polynesian islands with well-established anxiolytic and analgesic properties. Its main psychoactive principles, kavalactones, form a unique class of polyketides that interact with the human central nervous system through mechanisms distinct from those of conventional psychiatric drugs. However, an unknown biosynthetic machinery and difficulty in chemical synthesis hinder the therapeutic use of kavalactones. In addition, kava also produces flavokavains, which are chalconoids with anticancer properties structurally related to kavalactones. Here, we report de novo elucidation of the key enzymes of the kavalactone and flavokavain biosynthetic network. We present the structural basis for the evolutionary development of a pair of paralogous styrylpyrone synthases that establish the kavalactone scaffold and the catalytic mechanism of a regio- and stereo-specific kavalactone reductase that produces a subset of chiral kavalactones. We further demonstrate the feasibility of engineering styrylpyrone production in heterologous hosts, thus opening a way to develop kavalactone-based non-addictive psychiatric therapeutics through synthetic biology. | ||
| + | |||
| + | The biosynthetic origin of psychoactive kavalactones in kava.,Pluskal T, Torrens-Spence MP, Fallon TR, De Abreu A, Shi CH, Weng JK Nat Plants. 2019 Jul 22. pii: 10.1038/s41477-019-0474-0. doi:, 10.1038/s41477-019-0474-0. PMID:31332312<ref>PMID:31332312</ref> | ||
| + | |||
| + | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | ||
| + | </div> | ||
| + | <div class="pdbe-citations 6op5" style="background-color:#fffaf0;"></div> | ||
| + | == References == | ||
| + | <references/> | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
[[Category: Large Structures]] | [[Category: Large Structures]] | ||
| + | [[Category: Piper methysticum]] | ||
[[Category: Pluskal, T]] | [[Category: Pluskal, T]] | ||
[[Category: Weng, J K]] | [[Category: Weng, J K]] | ||
Revision as of 06:21, 7 August 2019
Crystal Structure of Piper methysticum Styrylpyrone Synthase 1 in complex with p-coumaroyl-CoA
| |||||||||||
